Chronic Lower Back Pain Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Eli Lilly, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Ltd, AnGes MG

DelveInsight's "Chronic Lower Back Pain Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Lower Back Pain, historical and forecasted epidemiology as well as the Chronic Lower Back Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Lower Back Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Lower Back Pain Market Forecast
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Chronic Lower Back Pain Market Report:
• The Chronic Lower Back Pain market size was valued approximately USD 6,227 Million in 2020 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In the 7MM, there were a total of 77,300,000 prevalent cases of CLBP in 2022. It is anticipated that there would be an increase in CLBP patients in the 7MM from 2019 to 2032
• Spain had the highest prevalence of CLBP cases in the EU4 with 8,930,000 cases, followed by the UK with 6,040,000 cases in 2022
• In 2022, there were 12,700,000 cases of Chronic Lower Back Pain in Japan.
• In February 2023, Camurus withdrew the CAM2038 application once it was expanded to cover chronic pain.
• In February 2023, Rexlemestrocel-L was given the RMAT designation by the FDA for regenerative medicine advanced therapy (chronic lower back pain).
• Key Chronic Lower Back Pain Companies: Eli Lilly and Company, Camurus/Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc, Pfizer, Endo Pharmaceuticals, Persica Pharmaceuticals, Collegium Pharma, DOV Pharma, Mallinckrodt, Grünenthal GmbH, AbbVie, and others
• Key Chronic Lower Back Pain Therapies: LY3016859, Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot), Semdexa (SP-102), Rexlemestrocel-L (MPC-06-ID), AMG0103, Duloxetine, buprenorphine, Celebrex 200mg, Oxymorphone ER, PP353, Oxycodone DETERx, Bicifadine, OROS hydromorphone, EN3324 (axomadol), ABT-712, and others
• The Chronic Lower Back Pain epidemiology based on gender analyzed that most of the CLBP cases include female population as compared to male patient pool
• The Chronic Lower Back Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Lower Back Pain pipeline products will significantly revolutionize the Chronic Lower Back Pain market dynamics.

Chronic Lower Back Pain Overview
Chronic lower back pain refers to persistent pain in the lower part of the back that lasts for 12 weeks or longer, despite treatment or self-care. It is a common condition that can affect people of all ages, but it is more prevalent in adults, particularly those over the age of 40. Chronic lower back pain can be debilitating and significantly impact daily activities, work, and overall quality of life.

Get a Free sample for the Chronic Lower Back Pain Market Report:
https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Lower Back Pain Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Lower Back Pain Epidemiology Segmentation:
The Chronic Lower Back Pain market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Chronic Lower Back Pain
• Prevalent Cases of Chronic Lower Back Pain by severity
• Gender-specific Prevalence of Chronic Lower Back Pain
• Diagnosed Cases of Episodic and Chronic Chronic Lower Back Pain

Download the report to understand which factors are driving Chronic Lower Back Pain epidemiology trends @ Chronic Lower Back Pain Epidemiology Forecast
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Lower Back Pain Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Lower Back Pain market or expected to get launched during the study period. The analysis covers Chronic Lower Back Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Lower Back Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Lower Back Pain Therapies and Key Companies
• LY3016859: Eli Lilly and Company
• Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot): Camurus/Braeburn Inc.
• Semdexa (SP-102): Scilex Holding
• Rexlemestrocel-L (MPC-06-ID): Mesoblast Limited
• AMG0103: AnGes MG, Inc
• Duloxetine: Eli Lilly and Company
• buprenorphine: Braeburn Pharmaceuticals
• Celebrex 200mg: Pfizer
• Oxymorphone ER: Endo Pharmaceuticals
• PP353: Persica Pharmaceuticals
• Oxycodone DETERx: Collegium Pharma
• Bicifadine: DOV Pharma
• OROS hydromorphone: Mallinckrodt
• EN3324 (axomadol): Grünenthal GmbH
• ABT-712: AbbVie

Discover more about therapies set to grab major Chronic Lower Back Pain market share @ Chronic Lower Back Pain Treatment Market
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Chronic Lower Back Pain Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Lower Back Pain Companies: Eli Lilly and Company, Camurus/Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc, Pfizer, Endo Pharmaceuticals, Persica Pharmaceuticals, Collegium Pharma, DOV Pharma, Mallinckrodt, Grünenthal GmbH, AbbVie, and others
• Key Chronic Lower Back Pain Therapies: LY3016859, Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot), Semdexa (SP-102), Rexlemestrocel-L (MPC-06-ID), AMG0103, Duloxetine, buprenorphine, Celebrex 200mg, Oxymorphone ER, PP353, Oxycodone DETERx, Bicifadine, OROS hydromorphone, EN3324 (axomadol), ABT-712, and others
• Chronic Lower Back Pain Therapeutic Assessment: Chronic Lower Back Pain current marketed and Chronic Lower Back Pain emerging therapies
• Chronic Lower Back Pain Market Dynamics: Chronic Lower Back Pain market drivers and Chronic Lower Back Pain market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Lower Back Pain Unmet Needs, KOL's views, Analyst's views, Chronic Lower Back Pain Market Access and Reimbursement

To know more about Chronic Lower Back Pain companies working in the treatment market, visit @ Chronic Lower Back Pain Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Chronic Lower Back Pain Market Report Introduction
2. Executive Summary for Chronic Lower Back Pain
3. SWOT analysis of Chronic Lower Back Pain
4. Chronic Lower Back Pain Patient Share (%) Overview at a Glance
5. Chronic Lower Back Pain Market Overview at a Glance
6. Chronic Lower Back Pain Disease Background and Overview
7. Chronic Lower Back Pain Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Lower Back Pain
9. Chronic Lower Back Pain Current Treatment and Medical Practices
10. Chronic Lower Back Pain Unmet Needs
11. Chronic Lower Back Pain Emerging Therapies
12. Chronic Lower Back Pain Market Outlook
13. Country-Wise Chronic Lower Back Pain Market Analysis (2019-2032)
14. Chronic Lower Back Pain Market Access and Reimbursement of Therapies
15. Chronic Lower Back Pain Market Drivers
16. Chronic Lower Back Pain Market Barriers
17. Chronic Lower Back Pain Appendix
18. Chronic Lower Back Pain Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Chronic Lower Back Pain Pipeline https://www.delveinsight.com/report-store/chronic-lower-back-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Chronic Lower Back Pain Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Lower Back Pain market. A detailed picture of the Chronic Lower Back Pain pipeline landscape is provided, which includes the disease overview and Chronic Lower Back Pain treatment guidelines.

Chronic Lower Back Pain Epidemiology https://www.delveinsight.com/report-store/chronic-lower-back-pain-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Chronic Lower Back Pain Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Chronic Lower Back Pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Insulin Glargine Biosimilar http://www.delveinsight.com/report-store/insulin-glargine-biosimilar-insight
DelveInsight's, "Insulin Glargine Biosimilar Insight, 2024," report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Insulin Glargine Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Cell And Gene Therapy For Multiple Myeloma m Market http://www.delveinsight.com/report-store/cell-and-gene-therapy-for-multiple-myeloma-market
DelveInsight's "Cell And Gene Therapy For Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cell And Gene Therapy For Multiple Myeloma, historical and forecasted epidemiology as well as the Cell And Gene Therapy For Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

End Stage Renal Disease Market http://www.delveinsight.com/report-store/end-stage-renal-disease-esrd-market
DelveInsight's "End-Stage Renal Disease (ESRD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the End-Stage Renal Disease (ESRD), historical and forecasted epidemiology as well as the End-Stage Renal Disease (ESRD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Fenebrutinib Market http://www.delveinsight.com/report-store/fenebrutinib-emerging-insight-and-market-forecast
"FENEBRUTINIB- Market Size, Forecast, and Emerging Insight - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets. A detailed picture of the FENEBRUTINIB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

Bcl-2 Inhibitors Market http://www.delveinsight.com/report-store/bcl2-inhibitors-market-forecast
DelveInsight's "BCL-2 Inhibitors Market Size, Target Population, Competitive Landscape and Market Forecast - 2034" report delivers an in-depth understanding of BCL-2 Inhibitors, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

Bispecifics Market http://www.delveinsight.com/report-store/bispecifics-market-forecast
DelveInsight's "Bispecifics Market Size, Target Population, Competitive Landscape and Market Forecast - 2034" report delivers an in-depth understanding of Bispecifics, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.